Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Opus Genetics, a clinical-stage biotech company specializing in gene therapies for inherited retinal diseases, announced a strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding to accelerate clinical development and potential commercialization of its gene therapy pipeline. The initial $35 million t…